サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1452586

欧州の神経膠腫治療市場：2030年までの予測-地域別分析：疾患別、治療タイプ別、グレード別、エンドユーザー別

Europe Glioma Treatment Market Forecast to 2030 - Regional Analysis - by Disease, Treatment Type, Grade, and End User
出版日: | 発行: The Insight Partners | ページ情報: 英文 96 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
欧州の神経膠腫治療市場：2030年までの予測-地域別分析：疾患別、治療タイプ別、グレード別、エンドユーザー別
出版日: 2024年01月15日
発行: The Insight Partners
ページ情報: 英文 96 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

欧州神経膠腫治療市場は、2022年の9億5,999万米ドルから2030年には19億510万米ドルに成長すると予測されています。2022年から2030年までのCAGRは8.9%と推定されます。

高悪性度神経膠腫の有病率の増加が欧州神経膠腫治療市場を後押し

高悪性度神経膠腫には、膠芽腫、退形成性星細胞腫、乏突起膠腫などの侵攻性脳腫瘍が含まれます。これらの腫瘍は、急速な増殖、浸潤性挙動、従来の治療法に対する抵抗性を特徴とします。高悪性度グリオーマは多面的な腫瘍であり、まだ完全には解明されておらず、これが発生率増加の主要原因となっています。さらに、人口の高齢化、環境暴露、遺伝的素因、診断能力の向上は、多数の症例をもたらす他の注目すべき因子です。神経膠腫、特に膠芽腫は、脳内に発生し、重要な神経機能を障害する能力を有するため、患者の生活に壊滅的な影響を及ぼすことで知られています。

脳腫瘍の中で最も頻度が高く危険なのが膠芽腫です。世界では、毎年25万例以上の原発性悪性脳腫瘍が新たに発見されており、その77％を神経膠腫が占めています。神経膠腫は、原発性悪性脳腫瘍の50％以上を占め、依然として稀な疾患です。

欧州神経膠腫治療市場概要

欧州の神経膠腫治療市場は、フランス、ドイツ、イタリア、スペイン、英国、その他の欧州に区分されます。同地域は世界市場で第2位のシェアを占めているが、これは脳腫瘍症例数の増加、フランスにおける脳腫瘍治療の技術進歩、英国における神経疾患の有病率の増加、ドイツにおける医療投資の急増などに起因しています。英国の医療セグメントは、発達した先端医療技術や医療機器を利用できます。英国国民保健サービスによると、英国では毎年1万1,000人以上が脳腫瘍と診断され、そのうち50％近くががんです。Globocan 2020のデータによると、英国では新たに約7,697人の脳腫瘍と中枢神経系がんの症例が記録されました。急増する罹患率の結果、複数の民間と政府機関ががん研究に投資しています。2021年4月に発表されたCancer Research UK（BCCR0001）の脳腫瘍と小児がん研究に関連する証拠文書によると、Cancer Research UKは2018年以降、脳腫瘍研究のための資金募集、卓越した研究センターと放射線研究ネットワークの立ち上げを通じて、脳腫瘍研究を奨励するために3,545万米ドルを拠出しています。同センターは、2019年から2020年にかけて、脳腫瘍研究に1,520万米ドル、小児と青年に影響を与えるがん研究に1,112万米ドルを投資し、英国全土の脳腫瘍セグメントで最大の研究資金提供者の1つとなりました。

欧州神経膠腫治療市場の収益と2030年までの予測（金額）

欧州神経膠腫治療市場のセグメンテーション

欧州神経膠腫治療市場は、疾患、治療タイプ、グレード、エンドユーザー、国別に区分されます。

疾患に基づき、欧州神経膠腫治療市場は星細胞腫、乏突起星細胞腫、乏突起膠腫にセグメント化されます。2022年の欧州神経膠腫治療市場で最大のシェアを占めたのは星細胞腫セグメントでした。

治療タイプに基づき、欧州神経膠腫治療市場は手術、化学療法、放射線療法、その他に区分されます。2022年の欧州神経膠腫治療市場で最大のシェアを占めたのは手術セグメントでした。

悪性度に基づき、欧州神経膠腫治療市場は低悪性度と高悪性度に区分されます。高悪性度セグメントは、2022年の欧州神経膠腫治療市場でより大きなシェアを占めました。

エンドユーザーに基づき、欧州神経膠腫治療市場は病院とクリニックと外来手術センターに区分されます。2022年の欧州神経膠腫治療市場では、病院とクリニックセグメントがより大きなシェアを占めています。

国別では、欧州神経膠腫治療市場はフランス、ドイツ、イタリア、スペイン、英国、その他の欧州に区分されます。2022年の欧州神経膠腫治療市場はドイツが独占。

Amgen Inc、Amneal Pharmaceuticals Inc、Biocon Ltd、F. Hoffmann-La Roche Ltd、Karyopharm Therapeutics Inc、Merck &Co Inc、Pfizer Inc、Sun Pharmaceutical Industries Ltd、Teva Pharmaceutical Industries Ltdは、欧州神経膠腫治療市場で事業を展開している大手企業の一部です。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

  • 主要な洞察

第3章 調査手法

  • 調査範囲
  • 2次調査
  • 1次調査

第4章 欧州神経膠腫治療市場-主要産業力学

  • 市場促進要因
    • 神経膠腫治療に対する政府の資金援助
    • 高悪性度神経膠腫の有病率の増加
  • 主要市場抑制要因
    • 診断コストの高さ
  • 主要市場機会
    • 新興国における医療セグメントの進歩
  • 今後の動向
    • 神経膠腫治療薬の承認急増
  • 影響分析

第5章 神経膠腫治療市場：欧州市場分析

  • 欧州神経膠腫治療市場収益、2022～2030年

第6章 欧州神経膠腫治療市場～2030年までの収益と予測：疾患別

  • イントロダクション
  • 欧州神経膠腫治療市場2022年・2030年収益シェア（%）：疾患別
  • 星細胞腫
  • 乏突起星細胞腫
  • 乏突起膠腫

第7章 欧州神経膠腫治療市場：2030年までの収益と予測：治療タイプ別

  • イントロダクション
  • 欧州神経膠腫治療市場2022年・2030年売上高シェア（%）：治療タイプ別
  • 外科療法
  • 化学療法
  • 放射線療法
  • その他

第8章 欧州神経膠腫治療市場：収益と2030年までの予測：グレード別

  • イントロダクション
  • 欧州神経膠腫治療市場2022年・2030年売上高シェア（%）：グレード別
  • 低悪性度
  • 高悪性度

第9章 欧州神経膠腫治療市場～2030年までの収益と予測：エンドユーザー別

  • イントロダクション
  • 欧州神経膠腫治療市場収益シェア（2022年・2030年）：エンドユーザー別
  • 病院とクリニック
  • 外来手術センター

第10章 欧州神経膠腫治療市場：国別分析

  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • その他の欧州

第11章 欧州神経膠腫治療市場の業界情勢

  • イントロダクション
  • 市場参入企業の成長戦略（%）
  • 有機的展開
  • 無機的展開

第12章 企業プロファイル

  • F. Hoffmann-La Roche Ltd
  • Sun Pharmaceutical Industries Ltd
  • Amgen Inc
  • Teva Pharmaceutical Industries Ltd
  • Pfizer Inc
  • Amneal Pharmaceuticals Inc
  • Karyopharm Therapeutics Inc
  • Biocon Ltd

第13章 付録

図表

List Of Tables

  • Table 1. Europe Glioma Treatment Market Segmentation
  • Table 2. UK: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Disease
  • Table 3. UK: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Treatment Type
  • Table 4. UK: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Grade
  • Table 5. UK: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Low Grade
  • Table 6. UK: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -High Grade
  • Table 7. UK: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - End User
  • Table 8. Germany: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Disease
  • Table 9. Germany: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Treatment Type
  • Table 10. Germany: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Grade
  • Table 11. Germany: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Low Grade
  • Table 12. Germany: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -High Grade
  • Table 13. Germany: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - End User
  • Table 14. France: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Disease
  • Table 15. France: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Treatment Type
  • Table 16. France: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Grade
  • Table 17. France: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Low Grade
  • Table 18. France: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -High Grade
  • Table 19. France: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - End User
  • Table 20. Italy: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Disease
  • Table 21. Italy: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Treatment Type
  • Table 22. Italy: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Grade
  • Table 23. Italy: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Low Grade
  • Table 24. Italy: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -High Grade
  • Table 25. Italy: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - End User
  • Table 26. Spain: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Disease
  • Table 27. Spain: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Treatment Type
  • Table 28. Spain: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Grade
  • Table 29. Spain: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Low Grade
  • Table 30. Spain: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -High Grade
  • Table 31. Spain: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - End User
  • Table 32. Rest of Europe: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Disease
  • Table 33. Rest of Europe: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Treatment Type
  • Table 34. Rest of Europe: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Grade
  • Table 35. Rest of Europe: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Low Grade
  • Table 36. Rest of Europe: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -High Grade
  • Table 37. Rest of Europe: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - End User
  • Table 38. Organic Developments Done By Companies
  • Table 39. Inorganic Developments Done By Companies
  • Table 40. Glossary of Terms, Europe glioma treatment market

List Of Figures

  • Figure 1. Europe Glioma Treatment Market Segmentation, By Country
  • Figure 2. Europe Glioma Treatment Market - Key Industry Dynamics
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Europe Glioma Treatment Market Revenue (US$ Mn), 2022 - 2030
  • Figure 5. Europe Glioma Treatment Market Revenue Share, by Disease 2022 & 2030 (%)
  • Figure 6. Astrocytoma: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 7. Oligodendroglioma: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 8. Oligodendroglioma: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 9. Europe Glioma Treatment Market Revenue Share, by Treatment Type 2022 & 2030 (%)
  • Figure 10. Surgery: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 11. Chemotherapy: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 12. Radiation Therapy: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 13. Others: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 14. Europe Glioma Treatment Market Revenue Share, by Grade 2022 & 2030 (%)
  • Figure 15. Low Grade: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 16. Grade I: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 17. Grade II: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 18. High Grade: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 19. Grade III: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 20. Grade IV: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 21. Europe Glioma Treatment Market Revenue Share, by End User 2022 & 2030 (%)
  • Figure 22. Hospital & Clinics: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 23. Ambulatory Surgical Centers: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 24. Europe Glioma Treatment Market, By Country, 2022 ($Mn)
  • Figure 25. Europe Glioma Treatment Market, By Key Countries, 2022 And 2030 (%)
  • Figure 26. UK: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 27. Germany: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 28. France: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 29. Italy: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 30. Spain: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 31. Rest of Europe: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 32. Growth Strategies Done by the Companies in the Market, (%)
目次
Product Code: BMIRE00029267

The Europe glioma treatment market is expected to grow from US$ 959.99 million in 2022 to US$ 1,905.10 million by 2030. It is estimated to grow at a CAGR of 8.9% from 2022 to 2030.

Increase in Prevalence of High-Grade Glioma Fuels Europe Glioma Treatment Market

High-grade gliomas include aggressive brain tumors such as glioblastomas, anaplastic astrocytomas, and oligodendrogliomas. These tumors are characterized by their rapid growth, infiltrative behavior, and resistance to conventional treatment methods. High-grade gliomas are multifaceted tumors that are not yet fully understood, which is a major reason for their increasing incidence. Moreover, aging populations, environmental exposure, genetic predispositions, and improved diagnostic capabilities are other notable factors that result in a large number of cases. Gliomas, particularly glioblastomas, are known for their devastating impact on patients\' lives due to their location within the brain and ability to disrupt critical neurological functions.

The most frequent and dangerous type of brain tumor is glioblastoma. Globally, more than 250,000 new cases of primary malignant brain tumors are detected each year, with gliomas accounting for 77% of these occurrences. It still remains a rare disease, accounting for over 50% of primary malignant brain tumors.

Europe Glioma Treatment Market Overview

The Europe glioma treatment market in Europe is segmented into France, Germany, Italy, Spain, the UK, and the Rest of Europe. The region holds the second-largest share of the global market, which can be attributed to the increasing number of brain tumor cases, technological advancements in brain tumor treatments in France, the increasing prevalence of neurological disorders in the UK, and surging healthcare investments in Germany. The healthcare sector in the UK has access to well-developed advanced medical technologies and devices. According to the United Kingdom National Health Service, more than 11,000 people are diagnosed with brain tumors in the UK each year, of which nearly 50% of tumors are cancerous. Per the Globocan 2020 data, the UK recorded about 7,697 new cases of brain and central nervous system cancer. As a result of the burgeoning incidence, several private and government organizations are investing in cancer research. As per the written evidence related to brain tumor and childhood cancer research from Cancer Research UK (BCCR0001), released in April 2021, Cancer Research UK has committed USD 35.45 million since 2018 to encourage brain tumor research through funding calls for brain tumor research and launching centers of excellence and a radiation research network. The center invested USD15.20 million in brain tumor research, and USD 11.12 million in cancer research affecting children and adolescents in 2019-2020 to become one of the largest research funders in the field of brain tumors across the UK.

Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Million)

Europe Glioma Treatment Market Segmentation

The Europe glioma treatment market is segmented into disease, treatment type, grade, end user, and country.

Based on disease, the Europe glioma treatment market is segmented into astrocytoma, oligoastrocytoma, and oligodendroglioma. The astrocytoma segment held the largest share of the Europe glioma treatment market in 2022.

Based on treatment type, the Europe glioma treatment market is segmented into surgery, chemotherapy, radiation therapy, and others. The surgery segment held the largest share of the Europe glioma treatment market in 2022.

Based on grade, the Europe glioma treatment market is segmented into low grade and high grade. The high grade segment held a larger share of the Europe glioma treatment market in 2022.

Based on end user, the Europe glioma treatment market is segmented into hospital & clinics and ambulatory surgical center. The hospital & clinics segment held a larger share of the Europe glioma treatment market in 2022.

Based on country, the Europe glioma treatment market is segmented into France, Germany, Italy, Spain, the UK, and the Rest of Europe. Germany dominated the Europe glioma treatment market in 2022.

Amgen Inc, Amneal Pharmaceuticals Inc, Biocon Ltd, F. Hoffmann-La Roche Ltd, Karyopharm Therapeutics Inc, Merck & Co Inc, Pfizer Inc, Sun Pharmaceutical Industries Ltd, and Teva Pharmaceutical Industries Ltd are some of the leading companies operating in the Europe glioma treatment market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Europe Glioma Treatment Market - Key Industry Dynamics

  • 4.1 Market Drivers
    • 4.1.1 Government Funding for Glioma Treatment
    • 4.1.2 Increase in Prevalence of High-Grade Glioma
  • 4.2 Key Market Restraints
    • 4.2.1 High Cost of Diagnosis
  • 4.3 Key Market Opportunities
    • 4.3.1 Advancements in Healthcare Sector in Emerging Economies
  • 4.4 Future Trends
    • 4.4.1 Surge in Drug Approvals for Glioma Treatment
  • 4.5 Impact Analysis:

5. Glioma Treatment Market - Europe Market Analysis

  • 5.1 Europe Glioma Treatment Market Revenue (US$ Mn), 2022 - 2030

6. Europe Glioma Treatment Market - Revenue and Forecast to 2030 - by Disease

  • 6.1 Overview
  • 6.2 Europe Glioma Treatment Market Revenue Share, by Disease 2022 & 2030 (%)
  • 6.3 Astrocytoma
    • 6.3.1 Overview
    • 6.3.2 Astrocytoma: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.4 Oligoastrocytoma
    • 6.4.1 Overview
    • 6.4.2 Oligoastrocytoma: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.5 Oligodendroglioma
    • 6.5.1 Overview
    • 6.5.2 Oligodendroglioma: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)

7. Europe Glioma Treatment Market - Revenue and Forecast to 2030 - by Treatment Type

  • 7.1 Overview
  • 7.2 Europe Glioma Treatment Market Revenue Share, by Treatment Type 2022 & 2030 (%)
  • 7.3 Surgery
    • 7.3.1 Overview
    • 7.3.2 Surgery: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Chemotherapy
    • 7.4.1 Overview
    • 7.4.2 Chemotherapy: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.5 Radiation Therapy
    • 7.5.1 Overview
    • 7.5.2 Radiation Therapy: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.6 Others
    • 7.6.1 Overview
    • 7.6.2 Others: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)

8. Europe Glioma Treatment Market - Revenue and Forecast to 2030 - by Grade

  • 8.1 Overview
  • 8.2 Europe Glioma Treatment Market Revenue Share, by Grade 2022 & 2030 (%)
  • 8.3 Low Grade
    • 8.3.1 Overview
    • 8.3.2 Low Grade: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
      • 8.3.2.1 Grade I: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
      • 8.3.2.2 Grade II: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 High Grade
    • 8.4.1 Overview
    • 8.4.2 High Grade: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
      • 8.4.2.1 Grade III: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
      • 8.4.2.2 Grade IV: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)

9. Europe Glioma Treatment Market - Revenue and Forecast to 2030 - by End User

  • 9.1 Overview
  • 9.2 Europe Glioma Treatment Market Revenue Share, by End User 2022 & 2030 (%)
  • 9.3 Hospital & Clinics
    • 9.3.1 Overview
    • 9.3.2 Hospital & Clinics: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.4 Ambulatory Surgical Centers
    • 9.4.1 Overview
    • 9.4.2 Ambulatory Surgical Centers: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)

10. Europe Glioma Treatment Market - Country Analysis

  • 10.1 Overview
    • 10.1.1 Europe Glioma Treatment Market, by Country
      • 10.1.1.1 UK
        • 10.1.1.1.1 UK: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.1.1.1.2 UK: Europe Glioma Treatment Market, by Disease
        • 10.1.1.1.3 UK: Europe Glioma Treatment Market, by Treatment Type
        • 10.1.1.1.4 UK: Europe Glioma Treatment Market, by Grade
        • 10.1.1.1.4.1 UK: Europe Glioma Treatment Market, by Low Grade
        • 10.1.1.1.4.2 UK: Europe Glioma Treatment Market, by High Grade
        • 10.1.1.1.5 UK: Europe Glioma Treatment Market, by End User
      • 10.1.1.2 Germany
        • 10.1.1.2.1 Germany: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.1.1.2.2 Germany: Europe Glioma Treatment Market, by Disease
        • 10.1.1.2.3 Germany: Europe Glioma Treatment Market, by Treatment Type
        • 10.1.1.2.4 Germany: Europe Glioma Treatment Market, by Grade
        • 10.1.1.2.4.1 Germany: Europe Glioma Treatment Market, by Low Grade
        • 10.1.1.2.4.2 Germany: Europe Glioma Treatment Market, by High Grade
        • 10.1.1.2.5 Germany: Europe Glioma Treatment Market, by End User
      • 10.1.1.3 France
        • 10.1.1.3.1 France: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.1.1.3.2 France: Europe Glioma Treatment Market, by Disease
        • 10.1.1.3.3 France: Europe Glioma Treatment Market, by Treatment Type
        • 10.1.1.3.4 France: Europe Glioma Treatment Market, by Grade
        • 10.1.1.3.4.1 France: Europe Glioma Treatment Market, by Low Grade
        • 10.1.1.3.4.2 France: Europe Glioma Treatment Market, by High Grade
        • 10.1.1.3.5 France: Europe Glioma Treatment Market, by End User
      • 10.1.1.4 Italy
        • 10.1.1.4.1 Italy: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.1.1.4.2 Italy: Europe Glioma Treatment Market, by Disease
        • 10.1.1.4.3 Italy: Europe Glioma Treatment Market, by Treatment Type
        • 10.1.1.4.4 Italy: Europe Glioma Treatment Market, by Grade
        • 10.1.1.4.4.1 Italy: Europe Glioma Treatment Market, by Low Grade
        • 10.1.1.4.4.2 Italy: Europe Glioma Treatment Market, by High Grade
        • 10.1.1.4.5 Italy: Europe Glioma Treatment Market, by End User
      • 10.1.1.5 Spain
        • 10.1.1.5.1 Spain: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.1.1.5.2 Spain: Europe Glioma Treatment Market, by Disease
        • 10.1.1.5.3 Spain: Europe Glioma Treatment Market, by Treatment Type
        • 10.1.1.5.4 Spain: Europe Glioma Treatment Market, by Grade
        • 10.1.1.5.4.1 Spain: Europe Glioma Treatment Market, by Low Grade
        • 10.1.1.5.4.2 Spain: Europe Glioma Treatment Market, by High Grade
        • 10.1.1.5.5 Spain: Europe Glioma Treatment Market, by End User
      • 10.1.1.6 Rest of Europe
        • 10.1.1.6.1 Rest of Europe: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.1.1.6.2 Rest of Europe: Europe Glioma Treatment Market, by Disease
        • 10.1.1.6.3 Rest of Europe: Europe Glioma Treatment Market, by Treatment Type
        • 10.1.1.6.4 Rest of Europe: Europe Glioma Treatment Market, by Grade
        • 10.1.1.6.4.1 Rest of Europe: Europe Glioma Treatment Market, by Low Grade
        • 10.1.1.6.4.2 Rest of Europe: Europe Glioma Treatment Market, by High Grade
        • 10.1.1.6.5 Rest of Europe: Europe Glioma Treatment Market, by End User

11. Europe Glioma Treatment Market Industry Landscape

  • 11.1 Overview
  • 11.2 Growth Strategies Done by the Companies in the Market, (%)
  • 11.3 Organic Developments
    • 11.3.1 Overview
  • 11.4 Inorganic Developments
    • 11.4.1 Overview

12. Company Profiles

  • 12.1 F. Hoffmann-La Roche Ltd
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Sun Pharmaceutical Industries Ltd
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Amgen Inc
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Teva Pharmaceutical Industries Ltd
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 Pfizer Inc
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 Amneal Pharmaceuticals Inc
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 Karyopharm Therapeutics Inc
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 Biocon Ltd
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments

13. Appendix

  • 13.1 About Us
  • 13.2 Glossary of Terms